Johnson & Johnson Q3 2026 Results show reported sales growth of 5.9% to $25.4 billion, and the company responded by raising its full-year 2026 guidance. Johnson & Johnson (NYSE: JNJ), based in New Brunswick, N.J., published the third-quarter figures on October 13, 2026. The release also covered a long list of regulatory, clinical and corporate milestones.
Operational sales growth, which excludes translational currency, was 6.0%. Adjusted operational growth, which also excludes the net impact of acquisitions and divestitures, was 6.1%.
Johnson & Johnson Q3 2026 Results: Sales Reach $25.4 Billion
Chairman and Chief Executive Officer Joaquin Duato credited the “accelerating momentum of our focused portfolio” for the quarter. He said innovations such as OTTAVA and positive Phase 3 multiple myeloma results, together with strategic investments, give the company a clearer line of sight to double-digit growth by the end of the decade. That is a forward-looking statement and not a guarantee.
Net earnings were $210 million, against $5,152 million in the third quarter of 2025, a decline of 95.9%. Diluted EPS fell 95.8% from $2.12. Adjusted net earnings, which exclude intangible amortization expense and special items, were $6,339 million against $6,801 million, down 6.8%. Adjusted EPS fell 7.5% from $2.80. This gap between GAAP and adjusted figures is the key reading of the Johnson & Johnson Q3 2026 Results.
Free cash flow was an estimated ~$15,100 million year to date as of October 13, 2026, against $14,226 million in the comparison period. The company defines it as operating cash flow less additions to property, plant and equipment. Cash flow from operations, the closest GAAP measure, will appear in subsequent SEC filings.
Overall Financial Results, Q3 2026 vs. Q3 2025
| Metric | Q3 2026 | Q3 2025 | % Change |
|---|---|---|---|
| Reported Sales ($M) | 25,399 | 23,993 | 5.9% |
| Net Earnings ($M) | 210 | 5,152 | (95.9)% |
| EPS, diluted (GAAP) | $0.09 | $2.12 | (95.8)% |
| Operational Sales (non-GAAP) | Not applicable | Not applicable | 6.0% |
| Adjusted Operational Sales (non-GAAP) | Not applicable | Not applicable | 6.1% |
| Adjusted Net Earnings ($M, non-GAAP) | 6,339 | 6,801 | (6.8)% |
| Adjusted EPS, diluted (non-GAAP) | $2.59 | $2.80 | (7.5)% |
| Free Cash Flow ($M, YTD, estimated) | ~15,100 | 14,226 | Not disclosed |
Regional and Segment Sales, Q3 2026 ($ in Millions)
| Category | Q3 2026 | Q3 2025 | Reported % | Operational % | Currency % | Adjusted Operational % |
|---|---|---|---|---|---|---|
| U.S. | 14,959 | 13,708 | 9.1% | 9.1 | none | 9.1 |
| International | 10,440 | 10,285 | 1.5% | 1.8 | (0.3) | 1.9 |
| Innovative Medicine | 16,757 | 15,563 | 7.7% | 7.9 | (0.2) | 8.0 |
| MedTech | 8,642 | 8,430 | 2.5% | 2.5 | 0.0 | 2.5 |
| Worldwide | 25,399 | 23,993 | 5.9% | 6.0 | (0.1) | 6.1 |
What the Johnson & Johnson Q3 2026 Results Show About Innovative Medicine and MedTech
U.S. sales rose 9.1% to $14,959 million, while international sales rose 1.5% to $10,440 million. The U.S. market therefore supplied most of the growth. Currency had only a small effect: a 0.3-point drag internationally and 0.1 point worldwide.
Innovative Medicine sales reached $16,757 million, up 7.7% reported and 7.9% operational. Divestitures reduced growth by 10 basis points. Segment detail is where the Johnson & Johnson Q3 2026 Results are most informative, because the company names the products behind the movement.
In Immunology, TREMFYA and new products within Other drove growth. In Oncology, the contributors were DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT/LAZCLUZE and ERLEADA. In Neuroscience, SPRAVATO and CAPLYTA helped. STELARA reduced growth by approximately 690 basis points. SIMPONI/SIMPONI ARIA, REMICADE, OPSUMIT/OPSYNVI and IMBRUVICA also offset gains.
MedTech sales were $8,642 million, up 2.5% both reported and operationally. Growth came from electrophysiology products and Shockwave in Cardiovascular, contact lenses in Vision, and trauma in Orthopaedics. The release gives no product-level dollar figures for these lines.
Johnson & Johnson Q3 2026 Results and the Raised 2026 Guidance
Johnson & Johnson raised its 2026 outlook in October from the figures it gave on July 29, 2026. Estimated reported sales now sit at $101.0 billion to $101.4 billion, a $101.2 billion midpoint. That is 7.4% growth, up from a $101.1 billion midpoint and 7.3% previously. Adjusted EPS guidance rose $0.06 to $11.10 at the midpoint, or 2.9% growth, from $11.04.
Operational sales guidance is $100.5 billion to $100.9 billion, a $100.7 billion midpoint and 6.9% growth, up from $100.6 billion and 6.8%. Adjusted operational sales growth is now 6.4% to 6.8%, with a 6.6% midpoint against 6.5% in July. Adjusted operational EPS is $10.95 to $11.05, with a $11.00 midpoint.
The reported-sales and adjusted EPS ranges use a euro average rate of $1.15, which the company calls illustrative. It does not give GAAP guidance because it cannot reliably predict legal proceedings, unusual gains and losses, acquisition-related expenses or purchase accounting adjustments. Investors reading the Johnson & Johnson Q3 2026 Results should treat all guidance as forward-looking.
2026 Guidance, October 2026 vs. July 29, 2026
| Metric | October 2026 Range | October Midpoint | July 29, 2026 Range | July Midpoint |
|---|---|---|---|---|
| Adjusted Operational Sales Growth | 6.4% – 6.8% | 6.6% | 6.2% – 6.8% | 6.5% |
| Operational Sales | $100.5B – $100.9B | $100.7B (6.9%) | $100.3B – $100.9B | $100.6B (6.8%) |
| Estimated Reported Sales | $101.0B – $101.4B | $101.2B (7.4%) | $100.8B – $101.4B | $101.1B (7.3%) |
| Adjusted Operational EPS | $10.95 – $11.05 | $11.00 (2.0%) | $10.86 – $11.01 | $10.94 (1.4%) |
| Adjusted EPS | $11.05 – $11.15 | $11.10 (2.9%) | $10.96 – $11.11 | $11.04 (2.3%) |
Pipeline, Regulatory and M&A Milestones Behind the Johnson & Johnson Q3 2026 Results
Three regulatory events headline the quarter. The FDA granted market authorization for the OTTAVA Robotic Surgical System, which the company calls the world’s first table-integrated soft tissue robotic system. The FDA approved IMAAVY (nipocalimab-aahu) as the first-ever treatment for warm autoimmune hemolytic anemia (wAIHA). RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) received FDA Priority Review as a potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer. The company also announced CE Marking for ACUVUE OASYS MAX contact lenses and MONARCH QUEST 3 for robotically-assisted bronchoscopy.
Data releases covered several franchises. CARVYKTI delivered five-year treatment-free remissions in 50% of patients in early-line relapsed/refractory multiple myeloma. TECVAYLI plus TALVEY reduced the risk of progression or death by 89% and the risk of death by 62% in earlier-line disease. The company also reported two-year ICOTYDE (icotrokinra) data in plaque psoriasis, TREMFYA data in axial psoriatic arthritis, and a CAPLYTA Phase 3 study in bipolar mania. Readers can follow late-stage compounds in the Innovative Medicine pipeline. This clinical momentum supports the Johnson & Johnson Q3 2026 Results narrative.
Corporate changes were notable too. Johnson & Johnson completed the acquisition of Firefly Bio, Inc. and announced a collaboration with Sail Biomedicines on in vivo CAR-T programs. It also announced a proposed resolution of ovarian talc litigation. Executive Vice President Jennifer Taubert is retiring, and Tom Cavanaugh was appointed EVP, Worldwide Chairman, Innovative Medicine. The forward-looking statements also reference a planned separation of the Orthopaedics business, but the release gives no timing or financial detail.
Notable Announcements in the Quarter
| Category | Announcement | Product / Company |
|---|---|---|
| Regulatory | FDA approval, first-ever wAIHA treatment | IMAAVY (nipocalimab-aahu) |
| Regulatory | FDA Priority Review, advanced head and neck cancer | RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) |
| Regulatory | FDA market authorization | OTTAVA Robotic Surgical System |
| Regulatory | CE Marking (flagged as subsequent to the quarter) | ACUVUE OASYS MAX Reusable Contact Lenses |
| Product | Announced | MONARCH QUEST 3 |
| Data | Two-year results, plaque psoriasis | ICOTYDE (icotrokinra) |
| Data | Five-year treatment-free remissions in 50% of patients | CARVYKTI (ciltacabtagene autoleucel) |
| Data | 89% lower risk of progression or death; 62% lower risk of death | TECVAYLI + TALVEY |
| Data | Phase 3 bipolar mania results | CAPLYTA (lumateperone) |
| Data | Axial psoriatic arthritis study | TREMFYA (guselkumab) |
| Deal | Acquisition completed | Firefly Bio, Inc. |
| Deal | In vivo CAR-T collaboration | Sail Biomedicines |
| Legal | Proposed resolution of ovarian talc litigation | Johnson & Johnson |
| Leadership | Taubert to retire; Cavanaugh appointed EVP, Worldwide Chairman, Innovative Medicine | Johnson & Johnson |
